case_images: PMC11794119_01
case_images: Comparisons of Patients' Pre- and Post-treatment: (A) CT scans from the time when lung malignancy was discovered to 4 months after brigatinib targeted therapy and imaging data from October 2023 were used as baseline assessments. (B) The red arrow indicates the bilateral fronto-parieto-temporal lobes and left occipital lobe with multiple metastases in the patient's brain before and after radiotherapy. The blue arrow indicates patchy enhancement in the left occipital cortex.
case_images: fonc-14-1503262-g001.jpg
case_images: PMC11794119_01_fonc-14-1503262-g001.jpg
case_images: f1
case_images: A more thorough line graph of imaging alterations and tumor size before and after therapy is displayed in  Figure 1  and  Figure 2 .
case_images: The long diameter of the patient's pulmonary nodules and multiple metastatic lesions before and after targeted therapy.
case_images: fonc-14-1503262-g002.jpg
case_images: PMC11794119_01_fonc-14-1503262-g002.jpg
case_images: f2
case_images: A more thorough line graph of imaging alterations and tumor size before and after therapy is displayed in  Figure 1  and  Figure 2 .
case_images: (A) The patient's hemoglobin content gradually increased during brigatinib targeted therapy. (B-D) The CA153 concentration was greater than 4000 U/ml at the first two measurements, the CA199 and CA125 concentration peaked at the time of examination in early November, and the levels of these two tumor markers decreased after brigatinib targeted therapy.
case_images: fonc-14-1503262-g003.jpg
case_images: PMC11794119_01_fonc-14-1503262-g003.jpg
case_images: f3
case_images: The patient's general health status was re-evaluated, and the PS score was 0.  Figure 3  presents a few of the aforementioned statistics visually.